These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33134477)

  • 1. The AT(N) framework for Alzheimer's disease in adults with Down syndrome.
    Rafii MS; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Lai F; Rosas HD; Zaman S; Petersen ME; Strydom A; Fortea J; Handen B; O'Bryant S
    Alzheimers Dement (Amst); 2020; 12(1):e12062. PubMed ID: 33134477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.
    Cummings J
    Alzheimers Dement; 2019 Jan; 15(1):172-178. PubMed ID: 29936146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
    Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau.
    McCollum LE; Das SR; Xie L; de Flores R; Wang J; Xie SX; Wisse LEM; Yushkevich PA; Wolk DA;
    Neuroimage Clin; 2021; 31():102717. PubMed ID: 34119903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
    Jack CR; Andrews JS; Beach TG; Buracchio T; Dunn B; Graf A; Hansson O; Ho C; Jagust W; McDade E; Molinuevo JL; Okonkwo OC; Pani L; Rafii MS; Scheltens P; Siemers E; Snyder HM; Sperling R; Teunissen CE; Carrillo MC
    Alzheimers Dement; 2024 Aug; 20(8):5143-5169. PubMed ID: 38934362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
    Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):587-97. PubMed ID: 26253588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
    Rozalem Aranha M; Iulita MF; Montal V; Pegueroles J; Bejanin A; Vaqué-Alcázar L; Grothe MJ; Carmona-Iragui M; Videla L; Benejam B; Arranz J; Padilla C; Valldeneu S; Barroeta I; Altuna M; Fernández S; Ribas L; Valle-Tamayo N; Alcolea D; González-Ortiz S; Bargalló N; Zetterberg H; Blennow K; Blesa R; Wisniewski T; Busciglio J; Cuello AC; Lleó A; Fortea J
    Alzheimers Dement; 2023 Nov; 19(11):4817-4827. PubMed ID: 37021589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?
    McRae-McKee K; Udeh-Momoh CT; Price G; Bajaj S; de Jager CA; Scott D; Hadjichrysanthou C; McNaughton E; Bracoud L; Ahmadi-Abhari S; de Wolf F; Anderson RM; Middleton LT;
    Alzheimers Dement; 2019 Oct; 15(10):1348-1356. PubMed ID: 31564609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease.
    Hammers DB; Kostadinova RV; Spencer RJ; Ikanga JN; Unverzagt FW; Risacher SL; Apostolova LG;
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2023; 30(6):866-884. PubMed ID: 36074015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
    Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum.
    Tang L; Wang ZB; Ma LZ; Cao XP; Tan L; Tan MS
    BMC Neurol; 2022 Dec; 22(1):508. PubMed ID: 36581903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
    Rafii MS; Zaman S; Handen BL
    J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How Helpful are Blood and Cerebrospinal Fluid Biomarkers for the Early Diagnosis of Alzheimer's Disease?].
    Tokuda T
    Brain Nerve; 2023 Aug; 75(8):915-921. PubMed ID: 37537737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.